A recent publication* from Barts Cancer Institute (BCI) highlights how the use of unique molecular identifiers (UMIs) can greatly increase the accuracy of detection of low-quality DNA with much improved allelic quantifications, e.g., for FFPE and ctDNA.

The paper features data generated by a custom hybridisation gene targeting panel from Nonacus¹. Testing this panel on FFPE and FF samples from follicular lymphoma biopsies found that a large number (>50-100) consensus sequences in FFPE samples had PCR duplicate reads.

*Applications and analysis of targeted genomic sequencing in cancer studies, Bewicke-Copley et al., Computational and Structural Biotechnology Journal, November 2019.

1. Nonacus specializes in high-quality tools for research involving cfDNA samples. Nonacus gene targeting panels for NGS include exome, exome CG and custom gene panels. All Nonacus Cell3™ Target Panels have been designed to ensure confident calling of all mutations down to 0.1% VAF. Nonacus is represented througout The Nordic countries by You Do Bio.